Use of bridged tricyclic amine derivatives as anti-ischemic agen

Details Use of bridged tricyclic amine derivatives as anti-ischemic agen Use of bridged tricyclic amine derivatives as anti-ischemic agen

1989-10-30

1991-10-08

Waddell, Frederick E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

514252, 514255, 514656, A61K 31495, A61K 3150, A61K 31135

Patent

active

050554689

ABSTRACT:
Certain bridged tricyclic amine compounds are described as being therapeutically effective in treatments of CNS disorders resulting from neurotoxic damage or neurodegenerative diseases, particularly those CNS disorders resulting from ischemic events. Compounds of particular interest for use as neuroprotective agents are those of the formula ##STR1## wherein each of R.sup.1 and R.sup.2 is independently selected from hydrido, loweralkyl, benzyl and phenyl; wherein each of R.sup.1 through R.sup.7 is independently selected from hydrido, loweralkyl, hydroxy, benzyl, phenyl, loweralkoxy, phenoxy, benzyloxy, halo and haloloweralkyl; wherein R.sup.18 may be selected from hydrido, loweralkyl, cycloalkyl of five or six carbon atoms, cycloalkylalkyl of six or seven carbon atoms, phenyl, hydroxyloweralkyl, and heteroaryl selected from saturated or fully unsaturated heterocyclic rings containing five to seven ring members of which one or two ring members are nitrogen atom; wherein each X is independently one or more groups selected from hydrido, hydroxy, loweralkyl, benzyl, phenyl, loweralkoxy, phenoxy, haloloweralkyl, halo, and lower-alkanoyl; and wherein each of R.sup.23 through R.sup.30 is independently selected from hydrido, lower alkyl, benzyl, phenyl and halo; wherein R.sup.18 together with one of R.sup.23, R.sup.24, R.sup.29 or R.sup.30 may form a fused heterocyclic ring containing five or six ring members; or a pharmaceutically-acceptable salt thereof.

REFERENCES:
patent: 3422104 (1969-01-01), Schroter et al.
S. M. Rothman and J. W. Olney, "Glutamate and the Pathophysiology of Hypoxia--Ischemic Brain Damage", Anals of Neurology, vol. 19, No. 2 (1986).
P. L. Wood et al, Neuropharm., 21, 1235-1238 (1982).
C. Carter et al, J. Pharm. Exp. Ther., 247 (3), 1222-1232 (1988).
K. Rehse et al, Arch. Pharm. (Neinheim), 320, 839-836 (1987).
S. Lecolir, Chim. Ther., 3, 34-38 (1968).
J. R. Boissier et al, J. Med. Chem., 10, 86-91 (1967).

Affiliated with

Also associated with

Rating

Use of bridged tricyclic amine derivatives as anti-ischemic agen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of bridged tricyclic amine derivatives as anti-ischemic agen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bridged tricyclic amine derivatives as anti-ischemic agen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-257196